S-EPMC7075837 - Clinical quantification of the integrin ?v?6 by [<sup>18</sup>F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study).

Dataset Information

Clinical quantification of the integrin ?v?6 by [¹⁸F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study).

ABSTRACT:

Purpose

The RGD-integrin, ?v?6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGF?). This study sought to quantify expression of ?v?6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the ?v?6-selective [¹⁸F]FB-A20FMDV2 PET ligand.

Methods

[¹⁸F]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (V_T) were used to quantify ?v?6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between ?v?6 expression and the distribution of fibrosis on high resolution computed tomography was conducted.

Results

A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. V_T and SUV of [¹⁸F]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric mean V_T (95% CI) was 0.88 (0.60, 1.29) mL/cm³ for healthy subjects, and 1.40 (1.22, 1.61) mL/cm³ for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthy V_T ratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [¹⁸F]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [¹⁸F]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [¹⁸F]FB-A20FMDV2 was safe and well tolerated.

Conclusions

Lung uptake of [¹⁸F]FB-A20FMDV2, a measure of expression of the integrin ?v?6, was markedly increased in subjects with PF compared with healthy subjects.

PROVIDER: S-EPMC7075837 | BioStudies |

REPOSITORIES: biostudies

ACCESS DATA

Similar Datasets

Project description:<h4>Purpose</h4>Immune checkpoint inhibitors can induce a T cell-mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using positron emission tomography (PET) might allow early insight into treatment efficacy. Activated tumor-infiltrating T cells express the high-affinity interleukin-2 receptor (IL-2R). Therefore, we performed a pilot study, using fluorine-18-labeled IL-2 ([<sup>18</sup>F]FB-IL2 PET), to evaluate whether a treatment-induced immune response can be detected.<h4>Methods</h4>Patients with metastatic melanoma received ~ 200 MBq [<sup>18</sup>F]FB-IL2 intravenously, followed by a PET/CT scan before and during immune checkpoint inhibitor therapy. [<sup>18</sup>F]FB-IL2 uptake was measured as standardized uptake value in healthy tissues (SUV<sub>mean</sub>) and tumor lesions (SUV<sub>max</sub>). Response to therapy was assessed using RECIST v1.1. Archival tumor tissues were used for immunohistochemical analyses of T cell infiltration.<h4>Results</h4>Baseline [<sup>18</sup>F]FB-IL2 PET scans were performed in 13 patients. SUV<sub>mean</sub> at baseline was highest in the kidneys (14.2, IQR: 11.6-18.0) and liver (10.6, IQR: 8.6-13.4). In lymphoid tissues, uptake was highest in spleen (10.9, IQR: 8.8-12.4) and bone marrow (2.5, IQR: 2.1-3.0). SUV<sub>max</sub> in tumor lesions (n = 41) at baseline was 1.9 (IQR: 1.7-2.3). In 11 patients, serial imaging was performed, three at week 6, seven at week 2, and one at week 4. Median [<sup>18</sup>F]FB-IL2 tumor uptake decreased from 1.8 (IQR: 1.7-2.1) at baseline to 1.7 (IQR: 1.4-2.1) during treatment (p = 0.043). Changes in [<sup>18</sup>F]FB-IL2 tumor uptake did not correlate with response. IL-2R expression in four archival tumor tissues was low and did not correlate with baseline [<sup>18</sup>F]FB-IL2 uptake. No [<sup>18</sup>F]FB-IL2-related side effects occurred.<h4>Conclusion</h4>PET imaging of the IL-2R, using [<sup>18</sup>F]FB-IL2, is safe and feasible. In this small patient group, serial [<sup>18</sup>F]FB-IL2-PET imaging did not detect a treatment-related immune response.<h4>Trial registration</h4>Clinicaltrials.gov : NCT02922283; EudraCT: 2014-003387.20.

Project description:<h4>Background</h4>Acute exacerbation (AE) is the most lethal postoperative complication in idiopathic pulmonary fibrosis (IPF); however, prediction before surgery is difficult. We investigated the role of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) in predicting postoperative AE in IPF.<h4>Method</h4>Clinical data of 48 IPF patients who underwent 18F-FDG PET/CT before thoracic surgery were retrospectively analyzed. Mean and maximal standardized uptake values (SUV<sub>mean</sub> and SUV<sub>max</sub>, respectively) were measured in the fibrotic area. Additionally, adjusted values-SUV ratio (SUVR, defined as SUV<sub>max</sub>-to-liver SUV<sub>mean</sub> ratio), tissue fraction-corrected SUV<sub>mean</sub> (SUV<sub>meanTF</sub>), and SUVR (SUVR<sub>TF</sub>)-were calculated.<h4>Results</h4>The mean age of the subjects was 67.8 years and 91.7% were male. After thoracic surgery, 21 (43.8%) patients experienced postoperative complications including prolonged air leakage (29.2%), death (14.6%), and AE (12.5%) within 30 days. Patients who experienced AE showed higher SUV<sub>max</sub>, SUVR, SUV<sub>meanTF</sub>, and SUVR<sub>TF</sub> than those who did not, but other clinical parameters were not different between patients with and without AE. The SUV parameters did not differ for other complications. The SUVR (odds ratio [OR] 29.262; P = 0.030), SUV<sub>meanTF</sub> (OR 3.709; P = 0.041) and SUVR<sub>TF</sub> (OR 20.592; P = 0.017) were significant predicting factors for postoperative AE following a multivariate logistic regression analysis. On receiver operating characteristics curve analysis, SUVR<sub>TF</sub> had the largest area under the curve (0.806, P = 0.007) for predicting postoperative AE among SUV parameters.<h4>Conclusions</h4>Our findings suggest that <sup>18</sup>F-FDG PET/CT may be useful in predicting postoperative AE in IPF patients and among SUVs, SUVR<sub>TF</sub> is the best parameter for predicting postoperative AE in IPF patients.